Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice

Summary We retrospectively reviewed our clinical experience with PGB when used as add-on therapy in 101 patients (56 women and 45 men) with refractory partial epilepsy, who have been followed up for at least 1 year. Mean age was 40 years (16–64); mean number of concomitant AEDs was 2.8. Most patient...

Full description

Saved in:
Bibliographic Details
Published in:Seizure (London, England) England), 2007-12, Vol.16 (8), p.709-712
Main Authors: Carreño, Mar, Maestro, Iratxe, Molins, Albert, Donaire, Antonio, Falip, Merce, Becerra, Juan Luis, Castillo, Joaquín
Format: Article
Language:English
Subjects:
Adolescent
Adult
Adverse effects
Ambulatory Care Facilities
Anticonvulsants - therapeutic use
Antiepileptic drugs
Efficacy
Epilepsies, Partial - drug therapy
Epilepsy
Female
Follow-Up Studies
gamma-Aminobutyric Acid - analogs & derivatives
gamma-Aminobutyric Acid - therapeutic use
Humans
Male
Middle Aged
Neurology
Pregabalin
Refractory
Retrospective Studies
Time Factors
Treatment
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary We retrospectively reviewed our clinical experience with PGB when used as add-on therapy in 101 patients (56 women and 45 men) with refractory partial epilepsy, who have been followed up for at least 1 year. Mean age was 40 years (16–64); mean number of concomitant AEDs was 2.8. Most patients (43) had temporal lobe epilepsy. Median number of seizures per month was 16 (3–240). Mean PGB dose used was 412.5 mg. Responder rate (percentage of patients with ≥50% seizure reduction) at 6 and 12 months was 52% and 39.6%, respectively. Seizure freedom for at least 6 and 12 months has been achieved by 12 patients (11.8%) and 6 patients (5.9%) respectively. At 1 year, 61 patients (60.4%) are still taking PGB. Forty patients have discontinued PGB, because of inefficacy (16 patients, 15.8%), adverse effects (15 patients, 14.8%) or both (9 patients, 8.9%). Sixty per cent of patients reported adverse events, being weight gain (>10% body weight) the most frequent, seen in 26 patients (25.7%). Dizziness/ataxia was seen in 20 (19.8%). Adverse effects were generally mild to moderate.
ISSN:1059-1311
1532-2688
DOI:10.1016/j.seizure.2007.05.011